Don’t forget fibratesA major meta-analysis of fibrate drugs has shown they modestly reduce the risk of major cardiovascular events, mainly through prevention of coronary artery disease and the need for revascularization. Report calls for free market-based drug policyGovernment intervention in prescription drug markets provides little benefit for Canadian consumers: Fraser Institute report Study flags cancer risk in female orthopedists New drug delivery system: the nanosponge? TD payment suggestions ‘interesting’ OMA says Bank recommends Ontario end fee-for-service model Low-dose combo therapy fends off diabetes Canadian trial of rosiglitazone-metformin pill not powered for adverse cardiovascular events Nurses extract health lessons from The Wizard of Oz Hybrid therapy tops for H. pylori infection Two-week combined strategy achieves superior eradication rates New protease inhibitor showing promise for hepatitis C Early study suggests experimental drug telaprevir offers option for patients who have not responded to standard treatment How much do adverse events cost? Focused research to determine economics of patient safety First Previous 823 824 825 826 827 Next Last
